CX3CR1 identifies PD-1 therapy–responsive CD8(+) T cells that withstand chemotherapy during cancer chemoimmunotherapy

Although immune checkpoint inhibitors have resulted in durable clinical benefits in a subset of patients with advanced cancer, some patients who did not respond to initial anti–PD-1 therapy have been found to benefit from the addition of salvage chemotherapy. However, the mechanism responsible for t...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:JCI Insight
Hauptverfasser: Yan, Yiyi, Cao, Siyu, Liu, Xin, Harrington, Susan M., Bindeman, Wendy E., Adjei, Alex A., Jang, Jin Sung, Jen, Jin, Li, Ying, Chanana, Pritha, Mansfield, Aaron S., Park, Sean S., Markovic, Svetomir N., Dronca, Roxana S., Dong, Haidong
Format: Artigo
Sprache:Inglês
Veröffentlicht: American Society for Clinical Investigation 2018
Schlagworte:
Research Article
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC5931117/
https://ncbi.nlm.nih.gov/pubmed/29669928
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/jci.insight.97828
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge